IART Integra Lifesciences Holdings Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: IART

Price (delayed)

$17.68

Market cap

$1.38B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$6.46

Enterprise value

$3.18B

?
Relative Growth: Rel. Growth: 15
Relative Strength: Rel. Strength: 88
Relative Valuation: Rel. Valuation: 32
Relative Profitability: Rel. Profitability: 17

Integra LifeSciences is a global leader in regenerative tissue technologies and neurosurgical solutions dedicated to limiting uncertainty for clinicians, so they can focus on providing the best patient care. Integra ...

Highlights
IART's quick ratio has soared by 168% YoY and by 29% from the previous quarter
Integra Lifesciences Holdings's net income has increased by 4% from the previous quarter
The equity has declined by 32% year-on-year
IART's gross margin is down by 3% YoY
Sector: Healthcare
Industry: Medical Devices
Website: http://www.integralife.com
Peers: SYK TFX XRAY CNMD

Key stats

What are the main financial stats of IART

IART stock price

How has the Integra Lifesciences Holdings stock price performed over time
Intraday
0.45%
1 week
-0.17%
1 month
17.09%
1 year
52.15%
YTD
42.35%
QTD
87.69%

Financial performance

How have Integra Lifesciences Holdings's revenue and profit performed over time
Revenue
$1.64B
Gross profit
$854.17M
Operating income
-$466.4M
Net income
-$495.8M
Gross margin
51.9%
Net margin
-30.1%
IART's operating margin is up by 6% since the previous quarter
The net margin is up by 4.7% since the previous quarter
The operating income has grown by 5% since the previous quarter
Integra Lifesciences Holdings's net income has increased by 4% from the previous quarter

Price vs fundamentals

How does IART's price correlate with its fundamentals

Growth

What is Integra Lifesciences Holdings's growth rate over time

Valuation

What is Integra Lifesciences Holdings stock price valuation
IART P/E details
P/E
N/A
P/B
1.32
P/S
0.83
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.93
IART's EPS is up by 4.2% since the previous quarter
The P/B is 47% higher than the last 4 quarters average of 0.9 but 34% lower than the 5-year quarterly average of 2.0
The equity has declined by 32% year-on-year
The price to sales (P/S) is 59% less than the 5-year quarterly average of 2.0 but 37% more than the last 4 quarters average of 0.6

Efficiency

How efficient is Integra Lifesciences Holdings business performance
IART's return on invested capital is up by 12% since the previous quarter
Integra Lifesciences Holdings's return on equity has decreased by 7% QoQ
IART's return on sales is up by 7% since the previous quarter

Dividends

What is IART's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IART.

Financial health

How did Integra Lifesciences Holdings financials performed over time
The company's total assets is 41% higher than its total liabilities
The current ratio has soared by 179% year-on-year and by 33% since the previous quarter
IART's quick ratio has soared by 168% YoY and by 29% from the previous quarter
The debt is 96% greater than the equity
Integra Lifesciences Holdings's debt to equity has increased by 48% YoY
The equity has declined by 32% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.